The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Official Title: A Study of Elranatamab Management With Outpatient and Intermittent Dosing in Relapsed/Refractory Multiple Myeloma
Study ID: NCT06421675
Brief Summary: A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.
Detailed Description: This is a multi-centre, single arm, phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. Potential study participants must have documented evidence of refractory or progressive disease during or within 60 days (measured from the end of the last cycle) of completing treatment with the last anti-myeloma drug regimen used just prior to study entry. Study participants will receive SC administration of elranatamab until disease progression, unacceptable toxicity or death. The primary short term outcome is hospitalization rate within the first 2 weeks of Cycle 1 of treatment; the primary long term outcome is rate of grade 3+ infections within the first 24 months of treatment. Study participants will be followed for survival for 36 months from the date of enrollment. A total of 40 study participants will be enrolled across approximately 5 Canadian clinical trial sites.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
Cross Cancer Institute, Edmonton, Alberta, Canada
Vancouver Cancer Center, Vancouver, British Columbia, Canada
Juravinski Cancer Center, Hamilton, Ontario, Canada
Ottawa Hospital, Ottawa, Ontario, Canada
Name: Hira Mian, MD
Affiliation: McMaster University
Role: PRINCIPAL_INVESTIGATOR
Name: Jim Wright, MD
Affiliation: OCOG - McMaster University
Role: STUDY_DIRECTOR